Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Hemodialysis Extraction Ratio

Known as: HDER 
The determination of the fractional content of a substance removed from the blood during a hemodialysis session.
National Institutes of Health

Related topics

Related topics

2 relations
CDISC SDTM Pharmacokinetic Parameter Long Name TerminologyClinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
Background: Numerous scales exist for classification of major bleeding events. There are limited data comparing the most commonly… Expand
2018
2018
Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation: A Nationwide Cohort Study
Background and Purpose— Edoxaban is a direct oral factor Xa inhibitor with proven efficacy and safety among patients with atrial… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2018
2018
Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial.
BACKGROUND Peri-operative management of anticoagulated patients with atrial fibrillation (AF) is challenging. To gain information… Expand
2017
2017
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial.
BACKGROUND Atrial fibrillation (AF) ablation procedures are increasingly being performed in patients receiving direct oral… Expand
Highly Cited
2016
Highly Cited
2016
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial
Background: Edoxaban, an oral factor Xa inhibitor with 50% renal clearance, was noninferior to well-managed warfarin for stroke… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 2
Highly Cited
2016
Highly Cited
2016
Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial
Background We studied the concomitant use of single antiplatelet therapy (SAPT) on the efficacy and safety of the anti‐Xa agent… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2016
Highly Cited
2016
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial…
Background and Purpose— Patients with atrial fibrillation and previous ischemic stroke (IS)/transient ischemic attack (TIA) are… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Highly Cited
2016
Highly Cited
2016
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF‐TIMI 48
In the ENGAGE AF‐TIMI 48 trial, edoxaban, a factor Xa inhibitor, was not found to be inferior to warfarin for the prevention of… Expand
2011
2011
Hospital de día de enfermedades respiratorias: impacto sobre la tasa de ingresos hospitalarios por exacerbaciones de la enfermedad pulmonar obstructiva crónica
Resumen Fundamento y objetivo Las exacerbaciones de la enfermedad pulmonar obstructiva cronica (EA-EPOC) constituyen un factor… Expand
2010
2010
Minimal Removal of Raltegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease
ABSTRACT Little is known about raltegravir removal by hemodialysis in patients with end-stage renal disease (ESRD). We therefore… Expand
  • table 1
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE